Overview (Fact): CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health, primarily through non-invasive molecular biomarker testing (e.g., donor-derived cell-free DNA or dd-cfDNA tests like AlloSure and gene expression profiling like AlloMap). The company operates mainly in the United States with testing services as its primary revenue driver and has expanded into specialty oncology and cell therapy. It employs approximately 760-765 people and is headquartered in Brisbane, California. Source: Yahoo Finance Profile Investor Relations
History (Fact): Incorporated in 1998 (originally as XDx, Inc. or Hippocratic Engineering, Inc.), the company changed its name to CareDx, Inc. in March 2014. It launched its first commercial product, AlloMap Heart, around 2005. Key milestones include its IPO on NASDAQ in July 2014 (opened at $10), multiple acquisitions (e.g., Allenex, ImmuMetrix, Ottr, MediGO), and a strategic pivot toward noninvasive testing. In 2026, it completed the acquisition of Naveris (adding NavDx for oncology) and divested its Lab Products business to Eurobio Scientific for ~$171M cash. Yahoo Profile IR News
Interpretation: The company's evolution from early gene-expression tests to dd-cfDNA surveillance positions it as a leader in transplant diagnostics, with recent moves suggesting a broadening platform beyond core transplant to higher-growth areas like oncology and cell therapy.
Uncertainty/Limitation: Historical details rely on company disclosures and secondary sources; exact acquisition timelines and financial impacts of divestitures/acquisitions may vary based on post-closing adjustments. Data current as of mid-July 2026 reporting.
| Period | CDNA Return | S&P 500 Return | Notes |
|---|---|---|---|
| YTD (as of ~July 2026) | 108.65% | 8.77% | Significant outperformance |
| 1-Year | 232.85% | 18.24% | Strong rally amid growth news |
| 3-Year | 288.44% | 64.63% | Longer-term strength |
| 5-Year | 50.13% | 72.08% | Mixed vs. benchmark |
Key Metrics (Fact): 52-week range approximately $11.26 - $40.38; beta ~2.43 (high volatility); average daily volume ~860K-1M shares. Yahoo Finance Macrotrends History
Interpretation: CDNA has substantially outperformed the broader market in recent periods, likely driven by revenue beats, guidance raises, and positive reimbursement/news catalysts in 2026.
Uncertainty: Past performance is not indicative of future results; returns calculated from available historical data snapshots and subject to market conditions at the time of measurement.
TTM Financial Highlights (Fact, as of latest available ~mid-2026):
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $412.82M | Testing services dominant |
| Net Income (TTM) | -$8.19M | Profit margin -1.98% |
| EPS (TTM) | -$0.16 | Diluted |
| Return on Assets (TTM) | -1.80% | — |
| Return on Equity (TTM) | -2.36% | — |
| Total Cash (MRQ) | $187.18M | Strong liquidity |
| Total Debt/Equity (MRQ) | 7.81% | Low leverage |
| Levered FCF (TTM) | $70.14M | Positive cash generation |
Recent Quarterly/Annual (Fact):
IR Quarterly Results Yahoo Financials
Interpretation: Revenue growth is accelerating with operational leverage improving (positive FCF, raised guidance), though the company remains near breakeven on net income, reflecting investments in growth and recent strategic shifts.
Data Limitations: TTM and quarterly figures are based on reported results up to Q1 2026 (announced ~April 2026); Q2 2026 results scheduled for July 30, 2026. Guidance includes assumptions around reimbursement and acquisition impacts. No assurance on future realization.
Consensus (Fact, as of mid-July 2026 data): Mixed ratings leaning toward Hold/Overweight. Average price target approximately $27–$28 (range $21–$38; some recent higher targets up to $45). Number of analysts: ~5–10 covering. Recent actions include BTIG maintaining Buy and raising target (e.g., to $45 post-news), others reiterating Hold amid valuation considerations. Yahoo Analysis MarketBeat Benzinga
| Rating Category | Approximate % or Count | Example Analysts/Actions |
|---|---|---|
| Buy/Strong Buy | ~50-57% | BTIG (Buy, raised PT), Stephens (Buy) |
| Hold/Neutral/Overweight | ~40-43% | H.C. Wainwright (Hold), others |
| Sell/Underperform | 0% | None prominent |
Interpretation: Positive sentiment boosted by Q1 beats, Medicare LCD finalization, and Naveris acquisition; however, some analysts note fair valuation post-rally and integration risks.
Limitations: Analyst ratings and targets change frequently and are opinions based on models/assumptions; not guarantees. Data aggregated from multiple sources as of July 2026; individual reports may differ.
Interpretation: Highly specialized B2B customer base in transplant medicine provides recurring testing revenue but creates concentration risk in a niche market.
| Competitor | Focus Area | Key Overlap |
|---|---|---|
| Natera (NTRA) | cfDNA testing, transplant/oncology | Direct competitor in dd-cfDNA transplant monitoring |
| Guardant Health (GH) | Liquid biopsy/oncology | Emerging overlap post-Naveris in oncology |
| Myriad Genetics (MYGN) | Genetic testing | Broader diagnostics |
| Veracyte (VCYT) | Genomic tests | Similar molecular diagnostics |
| Thermo Fisher Scientific (TMO) | Lab products/tools | Broader scale in HLA/typing |
| Others (e.g., NeoGenomics, Personalis) | Oncology/genomics | Competitive in precision medicine |
MarketBeat Competitors Seeking Alpha Peers
Interpretation: CareDx holds a specialized position in transplant diagnostics but faces competition from larger players in adjacent oncology/liquid biopsy spaces, especially after its Naveris acquisition.
Limitations: Competitor lists are based on industry classifications and analyst comparisons; exact market share data not publicly detailed in sources. Customer concentration and reimbursement dependencies introduce business risks.
For more: Official IR | Yahoo Finance | MarketBeat